Clinical Trial: Recurrent AA Amyloidosis After Renal Transplantation

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Recurrent AA Amyloidosis After Renal Transplantation: Effects on Allograft Survival

Brief Summary: End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.

Detailed Summary: AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.
Sponsor: Istanbul University

Current Primary Outcome: Allograft survival [ Time Frame: 1 - 5 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Allograft rejection [ Time Frame: 1 - 5 years ]

Original Secondary Outcome: Same as current

Information By: Istanbul University

Dates:
Date Received: March 4, 2016
Date Started: February 2016
Date Completion:
Last Updated: April 15, 2017
Last Verified: April 2017